LGALS3 and neoplasm: Based on human single-cell data from BCBM and liver metastases, alternative immune checkpoints such as LAG3–galectin-3 are highly active in tumor and infiltrating cells, suggesting their potential as important complements to PD-1/PD-L1 inhibitors [130, 135].